FDA approves Bumetanide nasal spray (Enbumyst) for marketing. This dosage form is effective in treating edema.

On September 15, 2025, Corstasis Therapeutics, an innovative biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Bumetanide Nasal Spray (Bumetanide)-Enbumyst for marketing. This approval marks Enbumyst as a new option for the treatment of edema associated with congestive heart failure (CHF) and liver and kidney disease, including nephrotic syndrome in adults. The launch of Enbumyst provides patients with a convenient self-administration regimen that makes up for the shortcomings of traditional oral and intravenous diuretics in the treatment of edema.

Enbumyst is a loop diuretic nasal spray designed for short-term use in adults to provide quick and effective relief of symptoms associated with fluid retention. The recommended use of this medication is 0.5 mg bumetanide once daily as a spray. This method of administration not only improves patient compliance but also reduces side effects caused by inappropriate drug use.

Bumetanide, the active ingredient of Enbumyst, is a powerful loop diuretic. Its mechanism of action is mainly reflected in the following aspects. First, bumetanide can effectively inhibit the reabsorption of sodium and chloride in the renal tubules and reduce the accumulation of fluid in the body. Secondly, bumetanide targets the loop of Henle, proximal tubule, and distal tubule of the renal tubule, which enhances its ability to produce rapid diuresis at different locations. In addition, bumetanide also inhibits carbonic anhydrase and aldosterone, further enhancing its diuretic effect.

In clinical studies,Enbumyst demonstrated rapid absorption and predictable diuretic response, with diuretic efficacy similar to intravenous bumetanide. This feature makes Enbumyst a new self-administered outpatient diuretic therapy that can effectively meet patients' needs for quick and convenient treatment. Through the nasal spray delivery method, patients can use it at home, which greatly improves the flexibility and safety of treatment.

Reference materials:https://www.drugs.com/enbumyst.html